A Phase 3 interventional study of Amiodarone and Placebo in Atrial Fibrillation New Onset, sponsored by Ana Belen Rivas Paterna. Completed at 6 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Ana Belen Rivas Paterna · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing amiodarone in Atrial Fibrillation — 12 open to participants now, 12 under way, 3 of them phase 3. Amiodarone · Atrial Fibrillation.
Among the 46 studies testing amiodarone in Atrial Fibrillation, this one is the 25th largest by enrollment, is the only one that started in 2020, is one of 12 in phase 3, and was the 28th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →12 of the 46 studies testing amiodarone in Atrial Fibrillation are open now, in 8 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 18+
Assiut University · Sites in Egypt
Ages 20–70 · Healthy volunteers
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Population Health Research Institute · Sites in Canada
Ages 18+
Hippocration General Hospital · Sites in Greece
Ages 18–85
By country, each count listing its studies:
Amiodarone: first FDA approval 1985 (CORDARONE). What it is approved for, and how studies give it, is on its page →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 13 · Phase 4 20
First in 1998; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 124 across the 46 interventional studies. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 46 has an industry lead sponsor. The 10 most frequent:
Ana Belen Rivas Paterna is the lead sponsor of 2 studies on the registry; none are open to participants now.
Ana Belen Rivas Paterna has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
2 of the studies testing amiodarone in Atrial Fibrillation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07487714Tomsk National Research Medical Center of the Russian Academy of SciencesComparative Efficacy of 100-, 200-, & 400-mg Amiodarone in Patients With Paroxysmal AF Depending on Plasma Concentration | 2027-05 |
| NCT06067438OHSU Knight Cancer InstituteAmiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer | 2027-08-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies testing amiodarone in Atrial Fibrillation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
New onset atrial fibrillation (NOAF) is a relatively frequent complication after transcatheter aortic valve implantation (TAVI). This complication has been related with worse short and long-term outcomes, including higher stroke, mortality, readmission and bleeding rates. The aim of this study is to evaluate the effectiveness of amiodarone in the prevention of the NOAF after TAVI.
The study is a multicenter, randomized double-blinded trial including 120 patients without prior AF that will undergo TAVI in a scheduled basis. Patients will be randomized to be treated with amiodarone orally from 6 days before to 6 days after the TAVI procedure versus placebo.
All the patients will be monitored with a 60-day holter to evaluate NOAF incidence. The main objective is NOAF incidence after TAVI at 30-day. Secondary endpoints are the incidence of NOAF, stroke, bleeding and all-cause and cardiovascular mortality in both groups at 60-day. Results of this study can contribute to optimize TAVI results in a short and long term, potentially improving the survival and quality of life in this group of frail patients with comorbidities, which makes them vulnerable to NOAF, stroke, bleeding, heart failure and readmission.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral Amiodarone 600mg / day, divided into 3 doses (200mg every 8 hours) for 6 days before the procedure and then 400mg / day, divided into 2 doses (200mg every 12 hours) during the 6 days following the implantation of TAVI.
Drug: Amiodarone
Patients assigned to the control group will receive placebo tablets identical to those of amiodarone. The administration of these tablets will follow the same scheme as in the amiodarone group. Therefore, they will receive placebo tablets orally, 1 tablet every 8 hours 6 days before the procedure and then 1 tablet every 12 hours during the 6 days following the implantation of TAVI
Drug: Placebo
Oral Amiodarone 600mg / day for 6 days before the procedure and then 400mg / day following the implantation of TAVI.
1 tablet of placebo/8 hours 6 days before the procedure and then 1 tablet/12 hours during the 6 days following the implantation of TAVI
Incidence of new onset atrial fibrillation
Compare the incidence of new onset atrial fibrillation (NOAF) on patients that receive oral amiodarone versus placebo. NOAF is defined as an irregular rhythm without P wave and irregular ventricular response during at least 30 seconds, detected in the electrocardiographic monitoring during the post-procedural period or in the 60 days ECG Holter in a patient without previous history of atrial fibrillation. NOAF incidence within 30-day after the TAVI procedure is the primary end-point.
Time frame: 30 days after transcatheter aortic valve implantation (TAVI)
Incidence of new onset atrial fibrillation
Compare the incidence of new onset atrial fibrillation (NOAF) on patients that receive oral amiodarone versus placebo. NOAF is defined as an irregular rhythm without P wave and irregular ventricular response during at least 30 seconds, detected in the electrocardiographic monitoring during the post-procedural period or in the 60 days ECG Holter in a patient without previous history of atrial fibrillation. NOAF incidence within 30-day after the TAVI procedure is the primary end-point.
Time frame: 60 days after transcatheter aortic valve implantation (TAVI)
Effect of the amiodarone
Analyze the effect of the amiodarone in the moment of appearance and the burden of AF after TAVI. AF burden, defined as the relative length of the AF registers in relation to the time in sinus rhythm.
Time frame: 1-year follow-up
Mortality and cardiovascular (CV) mortality.
Compare all-cause mortality and CV mortality between groups.
Time frame: 1-year follow-up
Number of patients with major adverse cardiac event (MACE)
MACE: Stroke, bleeding (major or life-threatening), and all-cause and cardiovascular mortality rate.
Time frame: at 30 days after NOAF
Number of patients with MACE
MACE: Stroke, bleeding (major or life-threatening), and all-cause and cardiovascular mortality rate.
Time frame: at 60 days after NOAF
Number of patients with MACE
MACE: Stroke, bleeding (major or life-threatening), and all-cause and cardiovascular mortality rate.
Time frame: at 6 months after NOAF
Number of patients with MACE
MACE: Stroke, bleeding (major or life-threatening), and all-cause and cardiovascular mortality rate.
Time frame: 1-year follow-up
Number of adverse events related to amiodarone
The safety evaluation will be realized by a meticulous vigilance of the adverse effects appeared in the study population.
Time frame: at 30 days after NOAF
Number of adverse events related to amiodarone
The safety evaluation will be realized by a meticulous vigilance of the adverse effects appeared in the study population.
Time frame: at 60 days after NOAF
Number of adverse events related to amiodarone
The safety evaluation will be realized by a meticulous vigilance of the adverse effects appeared in the study population.
Time frame: at 6 months after NOAF
Number of adverse events related to amiodarone
The safety evaluation will be realized by a meticulous vigilance of the adverse effects appeared in the study population.
Time frame: 1-year follow-up
Incidence of permanent pacemaker implantation in the both groups.
Need of permanent pacemaker implantation in the both groups.
Time frame: at 30 days after NOAF
Incidence of permanent pacemaker implantation in the both groups.
Need of permanent pacemaker implantation in the both groups.
Time frame: at 60 days after NOAF
Incidence of permanent pacemaker implantation in the both groups.
Need of permanent pacemaker implantation in the both groups.
Time frame: at 6 months after NOAF
Incidence of permanent pacemaker implantation in the both groups.
Need of permanent pacemaker implantation in the both groups.
Time frame: 1-year follow-up
Quality of life: EuroQoL 5D
Eq-5D: EuroQoL 5 Dimensions. Score between 0 and 1. The best score 1.
Time frame: at 30 days after NOA
Quality of life: Kansas City test
Score between 0 and 100. The best score 100.
Time frame: at 30 days after NOA
Quality of life: EuroQoL 5D
Eq-5D: EuroQoL 5 Dimensions. Score between 0 and 1. The best score 1.
Time frame: at 60 days after NOAF
Quality of life: Kansas City test
Score between 0 and 100. The best score 100.
Time frame: at 60 days after NOAF
Quality of life: EuroQoL 5D
Eq-5D: EuroQoL 5 Dimensions. Score between 0 and 1. The best score 1.
Time frame: at 6 months after NOAF
Quality of life: Kansas City test
Score between 0 and 100. The best score 100.
Time frame: at 6 months after NOAF
Quality of life: EuroQoL 5D
Eq-5D: EuroQoL 5 Dimensions. Score between 0 and 1. The best score 1.
Time frame: 1-year follow-up
Quality of life: Kansas City test
Score between 0 and 100. The best score 100.
Time frame: 1-year follow-up
Readmissions due to CV causes
Compare the number of readmissions due to CV causes
Time frame: 1-year follow-up
Functional change: New York Heart Association.
Evaluate the functional change according to the NYHA scale. Score between 0 and 4. The best score 1.
Time frame: at 30 days after NOA
Functional change: New York Heart Association.
Evaluate the functional change according to the NYHA scale. Score between 0 and 4. The best score 1.
Time frame: at 60 days after NOAF
Functional change: New York Heart Association.
Evaluate the functional change according to the NYHA scale. Score between 0 and 4. The best score 1.
Time frame: at 6 months after NOAF
Functional change: New York Heart Association.
Evaluate the functional change according to the NYHA scale. Score between 0 and 4. The best score 1.
Time frame: 1-year follow-up
Capacity for the exercise
Assess the change in capacity for the exercise, evaluated by the 6-minute walk test between groups
Time frame: at 30 days after NOA
Capacity for the exercise
Assess the change in capacity for the exercise, evaluated by the 6-minute walk test between groups
Time frame: at 60 days after NOAF
Capacity for the exercise
Assess the change in capacity for the exercise, evaluated by the 6-minute walk test between groups
Time frame: at 6 months after NOAF
Capacity for the exercise
Assess the change in capacity for the exercise, evaluated by the 6-minute walk test between groups
Time frame: 1-year follow-up
Incidence of Acute renal failure
Compare the number of events due to acute renal failure between groups
Time frame: baseline
Incidence of Acute renal failure
Compare the number of events due to acute renal failure between groups
Time frame: 30 days after NOA
Ran from Jan 2020 to primary completion in Oct 2022, 32 months.
Of 62 non-industry phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's 32 months is below that.
Counting every sponsor, half of 83 studies reached it within 42 months; a quarter within 32 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Jun 2019 → Jan 2020, primary completion Dec 2021 → Oct 2022 and completion Jun 2022 → Jun 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amiodarone
Ana Belen Rivas Paterna